LIPID-LOWERING THERAPY: FROM ORIGINS TO THE PRESENT DAY

The article deals with the treatment of dyslipidemia with HMG-CoA reductase inhibitors as well as non-statin lipid lowering drugs. Several lipid-lowering drugs have emerged in recent decades: bile acid sequestrants, fibrates, nicotinic acid, ezetimibe, bempedoic acid, volanesoren, evinacumab, PCSK 9 inhibitors evolocumab and alirocumab, and inclisiran. Although statins remain the gold standard of treatment, PCSK9-targeted therapy will play an increasingly important role in the correction of dyslipidemia. The review utilized information on the topic from publications based on PubMed and Google Scholar databases, depth of coverage 5 years.